Marian Kukucka

Marian Kukucka

Auto-generated profile, based on publicly available information

Marian Kukucka

Department of Anaesthesiology, Deutsches Herzzentrum Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
EPEvgenij Potapov
Evgenij Potapov
ASAlexander Stepanenko
Alexander Stepanenko
MDMichael Dandel
Michael Dandel
MKMarian Kukucka
Marian Kukucka
HLHans B. Lehmkuhl
Hans B. Lehmkuhl
RHRoland Hetzer
Roland Hetzer

1 January 2011 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MKMarian Kukucka
Marian Kukucka
ASAlexander Stepanenko
Alexander Stepanenko
EPEvgenij Potapov
Evgenij Potapov
TKThomas Krabatsch
Thomas Krabatsch
MRMathias Redlin
Mathias Redlin
HHHelmut Habazettl
Helmut Habazettl

13 September 2011 in Circulation
Verified
Journal Article
Open access
PDF file
TKThomas Krabatsch
Thomas Krabatsch
EPEvgenij Potapov
Evgenij Potapov
ASAlexander Stepanenko
Alexander Stepanenko
MSMartin Schweiger
Martin Schweiger
MKMarian Kukucka
Marian Kukucka
RHRoland Hetzer
Roland Hetzer
Background—Up to 30% of patients with end-stage heart failure experience biventricular failure that requires biventricular mechanical support. For these patients, only bulky extracorporeal or implantable displacement pumps or the total artificial heart have been available to date, which enables only limited quality of life for the patients. It was our goal to evaluate a method that would allow the use of 2 implantable centrifugal left ventricular assist devices as a biventricular assist system. Methods and Results—Seventeen patients have been implanted with 2 HeartWare HVAD pumps, 1 as a left ventricular assist device and 1 as a right ventricular assist device. Seventy-seven percent of the patients had idiopathic dilated or ischemic cardiomyopathy. Their age ranged from 29 to 73 years (mean 51.8±14.5 years), and 11 (64.7%) received intravenous catecholamine support preoperatively. The right ventricular assist device pump was implanted into the right ventricular free wall. The afterload of this pump was artificially increased by local reduction of the outflow graft diameter, and the effective length of its inflow cannula was reduced by the addition of two 5-mm silicon suture rings to the original HVAD implantation ring. All right ventricular assist device devices could be operated in appropriate speed ranges and delivered a flow of between 3.0 and 5.5 L/min. Thirty-day survival was 82%, and 59% of the patients could be discharged home after recovering from the operation. There was no clinically relevant hemolysis in any of the patients. Conclusions—Two HeartWare HVAD pumps can be used as a biventricular assist system. This implantable biventricular support gives the patients more comfort and mobility than usual biventricular ventricular assist devices with large and noisy displacement pumps.

1 January 2012 in JACC
Verified
Journal Article
Closed access
AUAxel Unbehaun
Axel Unbehaun
MPMiralem Pasic
Miralem Pasic
SDStephan Dreysse
Stephan Dreysse
TDThorsten Drews
Thorsten Drews
MKMarian Kukucka
Marian Kukucka
SBSemih Buz
Semih Buz

3 February 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
BNBoris A. Nasseri
Boris A. Nasseri
WEWolfram Ebell
Wolfram Ebell
MDMichael Dandel
Michael Dandel
MKMarian Kukucka
Marian Kukucka
RGRolf Gebker
Rolf Gebker
Christof StammChristof Stamm
Christof Stamm
Intra-myocardial transplantation of CD133+ bone marrow stem cells (BMC) yielded promising results in clinical pilot trials. We now performed the double-blinded, randomized, placebo-controlled CARDIO133 trial to determine its impact on left ventricular (LV) function and clinical symptoms. Sixty patients with chronic ischaemic heart disease and impaired LV function (left ventricular ejection fraction, LVEF <35%) were randomized to undergo either coronary artery bypass grafting (CABG) and injection of CD133+ BMC in the non-transmural, hypokinetic infarct border zone (CD133), or CABG and placebo injection (placebo). Pre-operative LVEF was 27 ± 6% in CD133 patients and 26 ± 6% in placebo patients. Outcome was assessed after 6 months, and the primary endpoint was LVEF measured by cardiac magnetic resonance imaging (MRI) at rest. The incidence of adverse events was similar in both groups. There was no difference in 6-min walking distance, Minnesota Living with Heart Failure score, or Canadian Cardiovascular Society (CCS) class between groups at follow-up, and New York Heart Association class improved more in the placebo group (P = 0.004). By cardiac MRI, LVEF at 6 months was 33 ± 8% in the placebo group and 31 ± 7% in verum patients (P = 0.3), with an average inter-group difference of −2.1% (95% CI −6.3 to 2.1). Systolic or diastolic LV dimensions at 6 months were not different, either. In the CD133 group, myocardial perfusion at rest recovered in more LV segments than in the placebo group (9 vs. 2%, P < 0.001). Scar mass decreased by 2.2 ± 5 g in CD133+ patients (P = 0.05), but was unchanged in the placebo group (0.3 ± 4 g, P = 0.7; inter-group difference in change = 2 g (95% CI −1.1 to 5)). By speckle-tracking echocardiography, cell-treated patients showed a better recovery of regional wall motion when the target area was posterior. Although there may be some improvements in scar size and regional perfusion, intra-myocardial injection of CD133+ BMC has no effect on global LV function and clinical symptoms. Improvements in regional myocardial function are only detectable in patients with posterior infarction, probably because the interventricular septum after anterior infarction is not accessible by trans-epicardial injection. This trial was registered at http://www.clinicaltrials.gov under NCT00462774.

1 June 2012 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
MPMiralem Pasic
Miralem Pasic
AUAxel Unbehaun
Axel Unbehaun
SDStephan Dreysse
Stephan Dreysse
SBSemih Buz
Semih Buz
TDThorsten Drews
Thorsten Drews
RHRoland Hetzer
Roland Hetzer
Background—: Iatrogenic damage of different structures of the aortic root, in the region of the so-called “device landing zone,” may occur during transcatheter aortic valve implantation (TAVI). It is mostly considered difficult to treat or even untreatable. Methods and Results—: We performed a retrospective analysis of the occurrence, clinical presentation, treatment, and outcome of iatrogenic rupture in the device landing zone in a series of 618 consecutive patients who underwent TAVI at our institution between April 2008 and October 2011. The incidence of rupture was 1% (6 patients). The correct diagnosis was established during TAVI procedures in 4 and postmortem in 2 patients. The major sign of the aortic rupture was apparent bleeding in 4 patients and failure of myocardial recovery after valve implantation in 1; it was asymptomatic in 1 patient. The iatrogenic rupture in the region of the device landing zone was treated surgically in 5 patients and only conservatively in the patient without symptoms. When the diagnosis was established correctly during TAVI, only 1 of 4 patients died (25%). The overall mortality rate was 50% (3 of 6 patients died). Conclusions—: Rupture of different structures in the device landing zone during TAVI is a life-threatening complication that can be treated successfully if it is immediately recognized and adequately managed.